The 50th European Society for Artificial Organs (ESAO) Annual Conference was successfully held in Aachen, Germany from September 11th to 14th, 2024. The conference brought together over 400 scientists, engineers, clinical doctors, and business representatives from around the world, aiming to promote interdisciplinary cooperation and innovation in artificial organs worldwide.
Dr. Xu Boling, founder and CEO of Xinqing Medical, was invited to attend and share with the experts present the self-developed in vitro fully magnetic levitation artificial heart MoyoAssist® by Xinqing Medical; The research results and latest developments, MoyoAssist® As the first fully magnetic levitation artificial heart approved for market in China, it has received extensive discussion and high praise from international experts in the field of artificial organs.
At the same time, Dr. Xu Jiahao, Senior Director of Science and Innovation at Xinqing Medical, was invited as a guest to report on Xinqing Medical's current company introduction, technological innovation, future research directions, etc., hoping to showcase China's innovation power on the international stage and attract overseas talents to join.
MoyoAssist®It is a fully magnetic levitation centrifugal pump that provides short-term extracorporeal ventricular assistance, which can be used for acute and severe conditions such as heart failure and cardiogenic shock that require temporary cardiac pumping function. This product adopts advanced computational fluid dynamics technology and full magnetic levitation technology worldwide to ensure blood compatibility. It can provide up to 30 days of support time and supports multiple modes, including patients who cannot withdraw extracorporeal circulation after cardiac surgery, transition to cardiac function recovery, and transition to other long-term alternative treatments.
As the first product of Xinqing Medical, it has been approved since 2017 and has undergone numerous research and development iterations, as well as rigorous clinical trial verification. Its effectiveness and safety have reached international standards, and it has been approved as an innovative medical device by the National Medical Products Administration. It was officially approved for market in April 2024, filling the gap in the field of short - and medium-term extracorporeal ventricular assist devices in China and meeting the clinical needs of a large population of heart failure patients in China. MoyoAssist® We have achieved international leading levels in new generation computational fluid dynamics, active magnetic levitation technology, control algorithms, and other aspects.
MoyoAssist®It is a new model for the clinical translation and application of innovative achievements in the combination of medicine and engineering in China. It can greatly enrich and improve the overall allocation level of medical resources in the treatment of acute and severe heart failure in China, providing a solid foundation for the scientific research and clinical application of the cardiovascular field in China, and has important medical and social value.關(guān)于ESAO
The European Society for Artificial Organs (ESAO) was established in Geneva, Switzerland in 1974. The European Society for Artificial Organs (ESAO) is a global association that encourages and publishes progress in the field of artificial organs and related areas. The primary goal of ESAO is to promote the maintenance and regeneration of human tissues and organs through artificial organ technology. Since its establishment, ESAO members have been committed to the development of artificial organs. Some of these studies have been launched and have helped patients maintain their lives while waiting for transplantation, or effectively replace lost organ function in patients with acute or chronic organ failure. With the advancement of basic science and technology, artificial organs will become more intelligent, enabling miniaturization, remote control, and bio hybrid systems, bringing progress and innovation to healthcare. The research scope of ESAO members includes cardiac assistive devices, computer modeling, tissue engineering, biometric measurements, artificial organs, biomaterials, and scaffolds.
disclaimer：
The content of this article is only for the purpose of conveying information or industry communication. Any content should not be considered as advertising, does not represent any explicit or implicit advertising, and should not be considered as any promise of sale or sales purpose. If the audience wants to know the exact situation, please consult professional medical institutions.
About Guoqian
Guoqian Medical Technology (Suzhou) Co., Ltd. is jointly invested and established by Dr. Zhang Xu and seven other national major talent engineering experts who have successfully innovated and started businesses in the fields of biomedical and medical devices, as well as shareholders in other fields.
Guoqian Medical is committed to investing in medical device innovation technology industry, entrepreneurial incubation, and precise empowerment. Guoqian Venture Capital Management (Suzhou) Co., Ltd., a wholly-owned subsidiary, is a venture capital firm specializing in early-stage equity investment in medical devices. Adhering to the business philosophy of "achieving others' dreams", Guoqian Venture Capital invests and aggregates industries through its managed equity investment funds, while Guoqian Medical creates an industrial ecosystem through incubation and empowerment. The two business platforms are highly coordinated, creating a high-end medical equipment industry cluster and ecosystem in Suzhou High tech Zone.